An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseases-Reference-Cited by-同舟云学术

An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseases

Published:2021-11 Issue: Volume:609 Page:121162
ISSN:0378-5173
Container-title:International Journal of Pharmaceutics
language:en
Short-container-title:International Journal of Pharmaceutics

Author:

Wu Helen Haixia,Ralph Kerry-Leigh,Sepuldeva Eliud,Hansen Gale,Li Hua,Huang Zhong-Fu,Liu Dongmei,Dziegelewski Michael,Ahlberg Jennifer,Frego Lee,Fogal Steve,van Tongeren Susan,Grimaldi Christine,Litzenberger Tobias,Presky David,Singh Sanjaya,Brodeur Scott,Kroe-Barrett Rachel

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference52 articles.

1. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival;Adams;J Immunol,2005

2. CD154: an immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis;Alaaeddine;Clin Dev Immunol,2012

3. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases;Albach;Eur J Clin Pharmacol,2018

4. Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation;An;J Biol Chem,2011

5. Molecular and biological characterization of a murine ligand for CD40;Armitage;Nature,1992

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemically Administered Anti-uPAR Antibody Plasma and Lung ELF Pharmacokinetics Characterized by Minimal Lung PBPK Model;AAPS PharmSciTech;2023-11-21

2. Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti‐CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Trial;Arthritis & Rheumatology;2023-08-17

3. Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches;European Journal of Immunology;2022-11-16

4. FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies;International Journal of Molecular Sciences;2022-10-25

5. Systemic lupus erythematosus-complicating immune thrombocytopenia: From pathogenesis to treatment;Journal of Autoimmunity;2022-10